Comparison of NSCLC patient groups with activated EGFR
mutations treated with three different tyrosine-kinase
inhibitors (TKI): Real-life data from the Czech Republic

a 2017

Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic

SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Karel HEJDUK, Miloš PEŠEK, Vítězslav KOLEK et. al.

Basic information

Original name

Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic

Authors

SKŘIČKOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Karel HEJDUK (203 Czech Republic, belonging to the institution), Miloš PEŠEK (203 Czech Republic), Vítězslav KOLEK (203 Czech Republic), Leona KOUBKOVÁ (203 Czech Republic), Jaromír ROUBEC (203 Czech Republic), Markéta ČERNOVSKÁ (203 Czech Republic), František SALAJKA (203 Czech Republic), Jana KREJČÍ (203 Czech Republic), Libor HAVEL (203 Czech Republic), Marcela TOMÍŠKOVÁ (203 Czech Republic, belonging to the institution), Monika ŠATÁNKOVÁ (203 Czech Republic), Andrea BENEJOVÁ (703 Slovakia), Ivona GRYGÁRKOVÁ (203 Czech Republic), Michal HRNČIARIK (203 Czech Republic), Milada ZEMANOVÁ (203 Czech Republic), Dimka SIXTOVÁ (203 Czech Republic) and Zdeněk MERTA (203 Czech Republic, belonging to the institution)

Edition

ERS international Congress 2017, 2017

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30203 Respiratory systems

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 12.244

RIV identification code

RIV/00216224:14110/17:00098882

Organization unit

Faculty of Medicine

ISSN

Keywords in English

NSCLC

Abstract

V originále

Background and Aim: From October 2013 there is a possibility to treat patients with NSCLC and with activated epidermal growth factor receptor (EGFR) mutations with three TKI (afatinib, eriotinib, gefitinib) in the Czech Republic. We have tried to find differences among patient groups treated with single TKI in 1st line of treatment. Patients and methods: As data source we used the TULUNG registry, which is focused on the data collection of patients with NSCLC treated with target therapy in the Czech Republic. We analysed 232 patients (gefitinib - 115 patients, afatinib - 77 patients, eriotinib - 40 patients.). Statistical significance was assessed using the Fisher's exact test or Kruskal-Wallis test (a=0.05).

Citovat

SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Karel HEJDUK, Miloš PEŠEK, Vítězslav KOLEK, Leona KOUBKOVÁ, Jaromír ROUBEC, Markéta ČERNOVSKÁ, František SALAJKA, Jana KREJČÍ, Libor HAVEL, Marcela TOMÍŠKOVÁ, Monika ŠATÁNKOVÁ, Andrea BENEJOVÁ, Ivona GRYGÁRKOVÁ, Michal HRNČIARIK, Milada ZEMANOVÁ, Dimka SIXTOVÁ and Zdeněk MERTA. Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic. In ERS international Congress 2017. 2017. ISSN 0903-1936.

@proceedings{1400030,
   author = {Skřičková, Jana and Chloupková, Renata and Hejduk, Karel and Pešek, Miloš and Kolek, Vítězslav and Koubková, Leona and Roubec, Jaromír and Černovská, Markéta and Salajka, František and Krejčí, Jana and Havel, Libor and Tomíšková, Marcela and Šatánková, Monika and Benejová, Andrea and Grygárková, Ivona and Hrnčiarik, Michal and Zemanová, Milada and Sixtová, Dimka and Merta, Zdeněk},
   booktitle = {ERS international Congress 2017},
   keywords = {NSCLC},
   language = {eng},
   title = {Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic},
   year = {2017}
}

TY  - CONF
ID  - 1400030
AU  - Skřičková, Jana - Chloupková, Renata - Hejduk, Karel - Pešek, Miloš - Kolek, Vítězslav - Koubková, Leona - Roubec, Jaromír - Černovská, Markéta - Salajka, František - Krejčí, Jana - Havel, Libor - Tomíšková, Marcela - Šatánková, Monika - Benejová, Andrea - Grygárková, Ivona - Hrnčiarik, Michal - Zemanová, Milada - Sixtová, Dimka - Merta, Zdeněk
PY  - 2017
TI  - Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic
KW  - NSCLC
N2  - Background and Aim: From October 2013 there is a possibility to treat patients with NSCLC and with activated epidermal growth factor receptor (EGFR) mutations with three TKI (afatinib, eriotinib, gefitinib) in the Czech Republic. We have tried to find differences among patient groups treated with single TKI in 1st line of treatment. Patients and methods: As data source we used the TULUNG registry, which is focused on the data collection of patients with NSCLC treated with target therapy in the Czech Republic. We analysed 232 patients (gefitinib - 115 patients, afatinib - 77 patients, eriotinib - 40 patients.). Statistical significance was assessed using the Fisher's exact test or Kruskal-Wallis test (a=0.05).
ER  -

SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Karel HEJDUK, Miloš PEŠEK, Vítězslav KOLEK, Leona KOUBKOVÁ, Jaromír ROUBEC, Markéta ČERNOVSKÁ, František SALAJKA, Jana KREJČÍ, Libor HAVEL, Marcela TOMÍŠKOVÁ, Monika ŠATÁNKOVÁ, Andrea BENEJOVÁ, Ivona GRYGÁRKOVÁ, Michal HRNČIARIK, Milada ZEMANOVÁ, Dimka SIXTOVÁ and Zdeněk MERTA. Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic. In \textit{ERS international Congress 2017}. 2017. ISSN~0903-1936.

Detailed Information on Publication Record